舒泰神拟定增募资不超12.53亿元，用于创新药研发和补充流动资金

Group 1 - Company Shuyatain (Beijing) Biopharmaceutical Co., Ltd. plans to issue shares to raise up to RMB 1.253 billion to alleviate funding pressures for new drug development and to supplement working capital [1] - The funds raised will allocate RMB 883 million for innovative drug development projects, including BDB-001 injection, STSA-1002 injection, STSP-0902 injection, and STSP-0902 eye drops [1] - The share issuance will not exceed 30% of the company's total share capital prior to the issuance, with a maximum of 143 million shares to be issued [1] Group 2 - Shuyatain has not launched any innovative drugs for years, relying on two older drugs, Sutai Sheng and Shuyat Qing, for core revenue [2] - The company reported a total net loss of nearly RMB 1 billion from 2020 to 2024, with a significant increase in losses in the first half of this year [3] - In the first half of this year, the company achieved revenue of RMB 126 million, a year-on-year decline of 31.14%, and a net loss of RMB 24.64 million, worsening from a loss of RMB 0.34 million in the same period last year [3] Group 3 - The company invested RMB 46.34 million in R&D in the first half of this year, accounting for 36.51% of total revenue, while continuing to advance nine Class I innovative biopharmaceuticals in clinical trials [3] - As of September 10, the company's stock closed at RMB 37.05, down 3.54% [4]